Characteristics of the included studies
| First author | Drug | Dose | Number of patients included | Mean age (years) | Minimum number attacks for month | Mean attacks for month controls | Primary end point | Randomised | Jadad score |
| Frank (1972)19 | Aminocaproic acid | 16 g/day | 5 | 35.6 | 1 | – | No. of courses with and without attacks in drug and placebo | No | 4 |
| Sheffer (1972)20 | Tranexamic acid | 3 g/day | 12 | 12–72 | – | 1.1 | No. of attacks for month | No | 1 |
| Gelfand (1976)21 | Danazol | 600 mg/day | 9 | 34.9 | 1 | – | No. of courses with and without attacks in drug and placebo | Yes | 5 |
| Sheffer (1977)22 | Methyltestosterone | 10 mg/day | 4 | – | 1 | 1.6 | No. of attacks for month | Yes | 3 |
| Weiler (2002)17 | Heparin | 400 U/kg/day | 15 | 32.6 | 1 | – | Average flare intensity | Yes | 5 |
| Waytes (1996)18 | V-H C1 inhibitor | 25 plasma unit/kg/every 3 days | 6 | – | 0.5 | – | Daily score for disease activity | Yes | 5 |
| Zuraw (2010)23 | C1 inhibitor | 1000 U/every 3–4 days | 22 | 38.1 | 2 | 4.24 | No. of attacks normalised for the number of days | Yes | 5 |
V-H, Vapour-heated.